Select Language
gp130
gp130 Overview
| English Name | Interleukin-6 receptor subunit beta | Approved Drugs | 8 |
| Drugs in Clinical Trials | 9 | Target Synonym | IL6ST，Oncostatin-M Receptor Subunit Alpha，CD130，Interleukin-6 Signal Transducer，Interleukin-6 Receptor Subunit Beta，Gp130 Of The Rheumatoid Arthritis Antigenic Peptide-Bearing Soluble Form，CD130 Antigen，Membrane Glycoprotein Gp130，SGP130，IL-6R-Beta，HIES4，Gp130， Oncostatin M Receptor，IL-6RB，GP130，Cytokine Receptor gp130，Interleukin 6 Signal Transducer，Membrane Glycoprotein 130，Interleukin 6 Signal Transducer (Gp130， Oncostatin M Receptor)，CDW130，IL-6 Receptor Subunit Beta，Interleukin Receptor Beta Chain，IL-6R Subunit Beta |
| Highest Development Stage | Approved | ||
| English Name | Interleukin-6 receptor subunit beta |
| Target Synonym | IL6ST，Oncostatin-M Receptor Subunit Alpha，CD130，Interleukin-6 Signal Transducer，Interleukin-6 Receptor Subunit Beta，Gp130 Of The Rheumatoid Arthritis Antigenic Peptide-Bearing Soluble Form，CD130 Antigen，Membrane Glycoprotein Gp130，SGP130，IL-6R-Beta，HIES4，Gp130， Oncostatin M Receptor，IL-6RB，GP130，Cytokine Receptor gp130，Interleukin 6 Signal Transducer，Membrane Glycoprotein 130，Interleukin 6 Signal Transducer (Gp130， Oncostatin M Receptor)，CDW130，IL-6 Receptor Subunit Beta，Interleukin Receptor Beta Chain，IL-6R Subunit Beta |
| Approved Drugs | 8 |
| Drugs in Clinical Trials | 9 |
| Highest Development Stage | Approved |
Product Inquiry
gp130 Background
Interleukin-6 receptor subunit beta (IL6ST) is also known as IL-6 receptor subunit beta, IL-6R subunit beta, IL-6R-beta, IL-6RB, Interleukin-6 signal transducer, Membrane glycoprotein 130 (gp130), CD130, Oncostatin-M receptor subunit alpha and Il6st,which is single-pass type I membrane protein. IL6ST /gp130 /CD130 can be found in tissues such as brain, heart, thymus, spleen, kidney, lung and liver and found in all the cell lines tested except BaF-B03.The expression of IL-6ST /gp130 is not restricted to IL6-responsive cells. The receptor systems for IL6, LIF, OSM, CNTF, IL11, CTF1 and BSF3 can utilize gp130 for initiating signal transmission. IL6ST /CD130 can bind to IL6 /IL6R (alpha chain) complex, resulting in the formation of high-affinity IL6 binding sites, and transduce the signal. IL6ST /GP130 does not bind IL6 and may have a role in embryonic development.
gp130 Synonyms
IL6ST,gp130,CD130,IL-6RB,IL-6R-beta,CDw130
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Recombinant humanized anti-IL-6R antibody (Hisun Pharma) | HS-628 | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Arthritis, Rheumatoid; Arthritis | Details |
| VDJ-001 | Phase 3 Clinical | Beijing Vdjbio Co Ltd | Arthritis, Rheumatoid; Multicentric Castleman's Disease (MCD) | Details | |
| Tocilizumab Biosimilar (Curateq Biologics) | BP08; BP-08 | Phase 3 Clinical | Arthritis, Rheumatoid | Details | |
| Tocilizumab biosimilar (GENERIUM Pharmaceuticals) | GNR-087 | Phase 3 Clinical | Generium Pharmaceuticals | Arthritis, Rheumatoid | Details |
| Tocilizumab biosimilar (AryoGen Pharmed) | Phase 3 Clinical | Aryogen Biopharma | Arthritis, Rheumatoid | Details | |
| Tocilizumab biosimilar(Hetero Biopharma) | Phase 3 Clinical | Hetero Biopharma Ltd | Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid | Details | |
| Levilimab | BCD-089 | Phase 3 Clinical | BIOCAD JSC | Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid | Details |
| Olamkicept | FE-999301; CR-5/18; TJ-301; FE-301 | Phase 2 Clinical | Conaris Research Institute | Gastrointestinal Diseases; Colitis, Ulcerative | Details |
| Atexakin alfa | SON-080; r-IL-6 | Phase 2 Clinical | Weizmann Institute Of Science | Peripheral Nervous System Diseases; Diabetic Neuropathies | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tocilizumab | rhPM-1; RO-48775533; RG-1569; MRA; HPM-1; MRA-SC; R-1569 | Approved | Chugai Pharmaceutical Co Ltd | Actemra, RoActemra, 雅美罗, Actemra/RoActemra, Acterma | Japan | Arthritis, Juvenile; Arthritis, Rheumatoid; Giant Cell Arteritis; Takayasu Arteritis; Cytokine Release Syndrome; Multicentric Castleman's Disease (MCD) | null | 2005-04-11 | Lymphoma; Graves Ophthalmopathy; Ascites; Takayasu Arteritis; Pancreatitis, Chronic; Coronavirus Infections; Pulmonary Arterial Hypertension; Coronary Disease; Lupus Erythematosus, Systemic; Breast Neoplasms; systemic sclerosis-associated interstitial lung disease; Multicentric Castleman's Disease (MCD); Fever; Uveitis, Posterior; Stroke; Pulmonary Disease, Chronic Obstructive; Osteoarthritis; Uveitis; Rejection in heart transplantation; Inflammation; Pleural Effusion, Malignant; Panuveitis; Diabetes Mellitus; Behcet Syndrome; Amyotrophic Lateral Sclerosis; Anemia, Sickle Cell; Carcinoma, Hepatocellular; Non-ST Elevated Myocardial Infarction; Myocardial Infarction; Hematologic Neoplasms; Solid tumours; Cytokine Release Syndrome; Motor Neuron Disease; HIV Infections; Diabetes Mellitus, Type 1; Acute Chest Syndrome; Craniopharyngioma; Polymyositis; Giant Cell Arteritis; Schnitzler Syndrome; Depressive Disorder, Major; Polyarticular Juvenile Idiopathic Arthritis; Non-radiographic axial spondyloarthritis; Uveitis | Details |
| Tocilizumab biosimilar (Bio-Thera Solutions) | BAT-1806; BIIB-800 | Approved | Bio-Thera Solutions Ltd | 施瑞立, TOFIDENCE | Mainland China | Arthritis, Rheumatoid; Arthritis, Juvenile; Cytokine Release Syndrome | Bio-Thera Solutions Ltd | 2023-01-16 | Cytokine Release Syndrome; Polyarticular Juvenile Idiopathic Arthritis; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Arthritis, Juvenile | Details |
| Sarilumab | SAR-153191; REGN-88 | Approved | Sanofi, Regeneron Pharmaceuticals Inc | Kevzara | United States | Arthritis, Rheumatoid | Sanofi-Synthelabo | 2017-05-22 | Polyarticular Juvenile Idiopathic Arthritis; Arthritis, Rheumatoid; Spondylitis, Ankylosing; Coronavirus Disease 2019 (COVID-19); Mastocytosis, Systemic; Sarcoidosis; Arthritis, Juvenile; Polymyalgia Rheumatica; Severe Acute Respiratory Syndrome; Uveitis | Details |
| Tocilizumab biosimilar (Livzon Group) | LZM-008 | Approved | Livzon Pharmaceutical Group Inc | 安维泰 | Mainland China | Arthritis, Rheumatoid | Livzon Mabpharm Inc | 2023-01-18 | Arthritis, Rheumatoid | Details |
| Tocilizumab biosimilar (Fresenius kabi) | MSB-11456; AT-220 (Arecor Therapeutics) | Approved | Merck Serono | Tyenne | EU | Coronavirus Disease 2019 (COVID-19); Cytokine Release Syndrome; Arthritis, Rheumatoid; Giant Cell Arteritis | Fresenius Kabi Deutschland Gmbh | 2023-09-15 | Brain Ischemia; Cytokine Release Syndrome; Giant Cell Arteritis; Polyarticular Juvenile Idiopathic Arthritis; Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Subarachnoid Hemorrhage | Details |
| Tocilizumab biosimilar (BioRay Pharm) | Approved | Hisun Biopharmaceutical Co Ltd | Mainland China | Arthritis, Rheumatoid | Hisun Biopharmaceutical Co Ltd | 2024-06-25 | Arthritis, Rheumatoid | Details | ||
| Tocilizumab biosimilar (Celltrion) | CT-P47; CT-P-47 | Approved | Celltrion Inc | Avtozma | United States | Giant Cell Arteritis; Polyarticular Juvenile Idiopathic Arthritis; Coronavirus Disease 2019 (COVID-19); Arthritis, Juvenile; Arthritis, Rheumatoid | Celltrion Inc | 2025-01-24 | Giant Cell Arteritis; Polyarticular Juvenile Idiopathic Arthritis; Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Arthritis, Juvenile | Details |
| Tocilizumab biosimilar (Maibo Taike) | CMAB-806; CMAB806 | Approved | Taizhou Maibo Taike Biotechnology Co Ltd, Jinyu Bowo Runze Biotechnology Co Ltd | Mainland China | Arthritis, Rheumatoid | Jinyu Bowo Runze Biotechnology Co Ltd | 2024-10-16 | Arthritis, Rheumatoid; Arthritis | Details |
- Overview
- Product Inquiry
- Marketed Drug Information
- Clinical Drug Information
Share to: